Nephros (NEPH) Expected to Release Quarterly Earnings on Thursday

Nephros (NASDAQ:NEPH) is expected to be posting its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect Nephros to announce earnings of $0.02 per share and revenue of $5.49 million for the quarter. Interested persons may visit the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

Nephros (NASDAQ:NEPH) last released its quarterly earnings data on Thursday, August 6th. The company reported $0.06 EPS for the quarter. The business had revenue of $6.02 million during the quarter, compared to the consensus estimate of $4.99 million. Nephros had a net margin of 8.38% and a return on equity of 10.60%. On average, analysts expect Nephros to post $0.15 EPS for the current fiscal year and $0.31 EPS for the next fiscal year.

Nephros Trading Down 9.7%

Shares of NASDAQ NEPH opened at $3.17 on Thursday. Nephros has a 12-month low of $2.66 and a 12-month high of $6.42. The firm’s 50-day moving average price is $3.96 and its 200-day moving average price is $3.70. The stock has a market capitalization of $34.46 million, a price-to-earnings ratio of 19.81 and a beta of 1.64.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the company. Benchmark reissued a “speculative buy” rating on shares of Nephros in a research note on Tuesday, August 18th. Northland Securities started coverage on Nephros in a research report on Friday, July 17th. They issued a “market perform” rating and a $4.00 price objective on the stock. Zacks Research raised Nephros to a “hold” rating in a research report on Monday, July 20th. Finally, Weiss Ratings upgraded Nephros from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, August 3rd. One equities research analyst has rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $4.00.

Nephros Company Profile

Nephros, Inc is a medical device company that develops and sells filtration products designed to improve water quality and reduce the risk of waterborne contamination. Its technologies are based primarily on ultrafiltration membranes that remove bacteria, viruses, endotoxins, cysts and other impurities from water.

The company serves the healthcare market with filtration systems for hemodialysis and infection-control applications. Its products are designed for use in hospitals, dialysis centers and other healthcare facilities where purified water is important for patient care and clinical operations.

Nephros also offers commercial water-filtration products for applications such as foodservice, hospitality, commercial buildings and healthcare facilities.